22 Mar

Analysts Have Mixed Opinions on United Therapeutics This Month

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts expect a potential upside of 2.45% for United Therapeutics (UTHR) based on the stock’s closing price on March 21.

Analysts revised the company’s target price upward from $125.27 in January and February to $126.00 in March. The current consensus analyst recommendation for the stock is a “hold.”

Analysts Have Mixed Opinions on United Therapeutics This Month

Of the 12 analysts covering United Therapeutics, two have given it “strong buys,” five have given it “holds,” four have given it “sells,” and one has given it a “strong sell.” The highest target price estimate for the company is $269, and the lowest is $95.

On March 21, United Therapeutics closed at $122.99, 1.44% higher than its previous closing price, 22.92% higher than its 52-week low of $100.06, and 5.39% lower than its 52-week high of $130.00. The company’s market cap is $5.34 billion.

Based on its closing price on March 21, United Therapeutics has reported returns of 5.09% in the last week, 4.33% in the last month, and 15.92% in the last quarter. The company has reported returns of -2.54% in the last half year, 14.19% in the last year, and 12.94% year-to-date.

Revenue estimates

In its fourth quarter, United Therapeutics reported revenue of $381.40 million, a YoY (year-over-year) fall of 17.93% but $25.59 million higher than the consensus estimate. The company reported non-GAAP (generally accepted accounting principles) EPS of $3.34, a YoY fall of 14.14% but still $0.79 higher than the consensus estimate. According to the company’s fourth-quarter earnings conference call, the loss of patent protection for Adcirca negatively affected its 2018 revenue performance.

Analysts expect United Therapeutics’ revenue to see YoY falls of -14.22% to $333.86 million in the first quarter, -26.90% to $324.92 million in the second quarter, -26.42% to $303.68 million in the third quarter, and -19.78% to $305.97 million in the fourth quarter of 2019. They expect United Therapeutics’ revenue to see YoY falls of -20.89% to $1.29 billion in 2019, -7.82% to $1.19 billion in 2020, and -3.17% to $1.15 billion in 2021.

Next, we’ll discuss analysts’ recommendations and projections for Jazz Pharmaceutical.

Latest articles

US crude oil production has more than doubled since 2009 and grew by 1.1% over the last year. Currently, there are 133 operable refineries in the US.

The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

Higher revenues, increased ticket prices, and lower fuel costs are likely to drive American Airlines' Q3 earnings higher despite its Boeing MAX woes.

HEXO plans to report its Q4 earnings before the market opens on October 24. October has been tough for Hexo, with its stock falling 31.2% as of October 18.

Today, Advanced Micro Devices (AMD) rose 4% to over $32, making it one of the top Nasdaq gainers. Morgan Stanley raised its price target for AMD stock.

Early in 2019, President Donald Trump warned that China could overtake the US as a global power. He vowed that this would not happen under his leadership.